The absolute bioavailability of microcrystalline theophylline

Jonkman, Jhg; Berg, Wilhelm; Schoenmaker, R.; Greving, Je; Zeeuw, Rokus A. de; Orie, N. G. M.

doi:10.1185/03007997909115912

Cited by 7 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rapid and slow release theophylline preparations used in this study have been shown to possess equivalent and very high bioavailability (Jonkman, Berg, Schoenmaker, Greving, De Zeeuw & Orie, 1979;Svedmyr, Mellstrand & Svedmyr, 1979). Both single dose and steady state pharmacokinetic studies have been performed with these formulations and indicate that approximate peak serum theophylline levels will occur at 2 h with rapid release and 4 to 6 hs with slow release theophylline (Marlin, Hartnett, Berend & Hacket, 1978;McDevitt, Elwood & Russell, 1979;Svedmyr et al, 1979).…”

Section: Discussionmentioning

confidence: 99%

Serum level monitoring of a new slow release theophylline formulation in patients with chronic lung disease.

Marlin¹,

Butcher²,

Klumpp³

et al. 1980

Brit J Clinical Pharma

View full text Add to dashboard Cite

1 Serum theophylline levels were performed in 26 patients with chronic lung disease receiving rapid release theophylline (125 mg 6 hourly) and 28 patients receiving slow release theophylline (250 mg 12 hourly) under steady state conditions. 2 For rapid release theophylline the mean + s.d. serum theophylline levels at 0 and 2 h were 41.0 + 21.7 and 52.3 + 20.9 mol P1-respectively and for slow release theophylline at 0, 4 and 6 h 43.7 + 25.5, 50.9 + 23.0 and 51.7 + 26.4 pmol I1 respectively. 3 Serum theophylline monitoring with slow release theophylline was performed in 70 patients with chronic lung disease. The initial dose was 250 mg administered 12 hourly. 4 The mean + s.d. steady state serum theophylline level achieved was 76.0 + 18.8 jimol -1 and the mean + s.d. dose to produce this level was 9.4 + 2.3 mg kg-' day-'. There was no correlation between dosage and serum theophylline level. 5 Sixty percent of patients required a dosage change for stabilization (375 to 1000 mg/day). Seventeen patients reported unwanted effects (nausea or tremor), which either settled quickly or resolved with dosage reduction. 6 Serum theophylline levels were obtained at different dosages in 44 patients and 18 patients demonstrated dose-dependent kinetics. 7 An initial dose of 500 mg/day is recommended and dosage increments should not exceed 125 mg/day with monitoring by serum theophylline levels.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum level monitoring of a new slow release theophylline formulation in patients with chronic lung disease.

Marlin¹,

Butcher²,

Klumpp³

et al. 1980

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…The bioavailability of theophylline (Theolair®) was considered as being 100% (Jonkman et al, 1979). The volume of distribution was calculated as:…”

Section: Subjectsmentioning

confidence: 99%

Lack of effect of terfenadine on theophylline pharmacokinetics and metabolism in normal subjects.

Brion

Naline

Pays

et al. 1989

Brit J Clinical Pharma

View full text Add to dashboard Cite

The pharmacokinetics of oral theophylline (250 mg) and the production of its metabolites (3-methylxanthine, 1-methyluric acid, 1,3-dimethyluric acid) were studied before and after the administration of oral terfenadine (120 mg twice daily for 16 days) in 10 healthy volunteers. Comparison of volumes of distribution, elimination half-lives, areas under the plasma concentration-time curves, plasma clearance of theophylline and elimination of theophylline metabolites indicated that terfenadine had no significant effect on theophylline pharmacokinetics and metabolism.

show abstract

Plasma theophylline concentrations following the oral administration of microcrystalline theophylline and a new sustained-release theophylline preparation to normal subjects

Russell¹,

Elwood²,

Kinney³

et al. 1980

Eur J Clin Pharmacol

View full text Add to dashboard Cite

The absolute bioavailability of microcrystalline theophylline

Cited by 7 publications

References 4 publications

Serum level monitoring of a new slow release theophylline formulation in patients with chronic lung disease.

Serum level monitoring of a new slow release theophylline formulation in patients with chronic lung disease.

Lack of effect of terfenadine on theophylline pharmacokinetics and metabolism in normal subjects.

Plasma theophylline concentrations following the oral administration of microcrystalline theophylline and a new sustained-release theophylline preparation to normal subjects

Contact Info

Product

Resources

About